Abbott Laboratories (NYSE:ABT) is expected to report Q1 earnings Wednesday, April 21 before the market open, with a conference call scheduled for 9 am ET.
Analysts are looking for EPS of 80c on revenue of $7.73B. The consensus range is 79c-81c for EPS, and $7.46B-$7.99B for revenue. Positive catalysts for this quarters results should come from Humira sales, the Xience stent and cost cutting measures. Since Humira sales make up about 35% of Abbot's revenue, investors will be watching closely to see if the company is on track to meets its yearly Humira sales estimates of 20% growth.
On April 6, J.P. Morgan said biotech is positioned for further outperformance relative to the broader market and mentioned Abbott as its number two pick.